Literature DB >> 28532569

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.

Nuria Chic1, Clara Mayo-de-Las-Casas2, Noemí Reguart3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28532569     DOI： 10.1016/j.jtho.2017.02.014

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  15 in total

Review 1.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors:  Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

2.  Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.

Authors:  D A Ezeife; B Melosky; R Tudor; S Lin; A Lau; T Panzarella; N B Leighl
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 3.  Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Authors:  Martyna Filipska; Rafael Rosell
Journal:  Mol Oncol       Date:  2021-05-26       Impact factor: 6.603

Review 4.  Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.

Authors:  Takaki Akamine; Gouji Toyokawa; Tetsuzo Tagawa; Takashi Seto
Journal:  Onco Targets Ther       Date:  2018-08-22       Impact factor: 4.147

5.  Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence.

Authors:  Peng Chen; Fuchao Chen; Jiexin Lei; Benhong Zhou
Journal:  Onco Targets Ther       Date:  2018-12-12       Impact factor: 4.147

6.  The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

Authors:  Marzia Del Re; Paola Bordi; Eleonora Rofi; Giuliana Restante; Simona Valleggi; Roberta Minari; Stefania Crucitta; Elena Arrigoni; Antonio Chella; Riccardo Morganti; Marcello Tiseo; Iacopo Petrini; Romano Danesi
Journal:  Br J Cancer       Date:  2018-11-06       Impact factor: 7.640

7.  AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.

Authors:  Jordi Bertran-Alamillo; Valérie Cattan; Marie Schoumacher; Jordi Codony-Servat; Ana Giménez-Capitán; Frédérique Cantero; Mike Burbridge; Sonia Rodríguez; Cristina Teixidó; Ruth Roman; Josep Castellví; Silvia García-Román; Carles Codony-Servat; Santiago Viteri; Andrés-Felipe Cardona; Niki Karachaliou; Rafael Rosell; Miguel-Angel Molina-Vila
Journal:  Nat Commun       Date:  2019-04-18       Impact factor: 14.919

8.  Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.

Authors:  Jacqueline H Starrett; Alexis A Guernet; Maria Emanuela Cuomo; Kamrine E Poels; Iris K van Alderwerelt van Rosenburgh; Amy Nagelberg; Dylan Farnsworth; Kristin S Price; Hina Khan; Kumar Dilip Ashtekar; Mmaserame Gaefele; Deborah Ayeni; Tyler F Stewart; Alexandra Kuhlmann; Susan M Kaech; Arun M Unni; Robert Homer; William W Lockwood; Franziska Michor; Sarah B Goldberg; Mark A Lemmon; Paul D Smith; Darren A E Cross; Katerina Politi
Journal:  Cancer Res       Date:  2020-03-19       Impact factor: 12.701

Review 9.  Third generation EGFR TKIs: current data and future directions.

Authors:  Chee-Seng Tan; Nesaretnam Barr Kumarakulasinghe; Yi-Qing Huang; Yvonne Li En Ang; Joan Rou-En Choo; Boon-Cher Goh; Ross A Soo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

10.  Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions.

Authors:  Sergio Villatoro; Clara Mayo-de-Las-Casas; Núria Jordana-Ariza; Santiago Viteri-Ramírez; Mónica Garzón-Ibañez; Irene Moya-Horno; Beatriz García-Peláez; María González-Cao; Umberto Malapelle; Ariadna Balada-Bel; Alejandro Martínez-Bueno; Raquel Campos; Noemí Reguart; Margarita Majem; Remei Blanco; Ana Blasco; María J Catalán; Xavier González; Giancarlo Troncone; Niki Karachaliou; Rafael Rosell; Miguel A Molina-Vila
Journal:  Mol Oncol       Date:  2019-10-11       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.